Head of Market Access Nephrology, Vifor Pharma
Dr. Thilo Schaufler, Head of Market Access Nephrology, Vifor Pharma
Thilo Schaufler is a seasoned professional with 15 years’ experience in market access and health policy roles, providing strategic leadership to global and local cross-functional teams to support business growth. He has co-led successful product launches, indication expansions as well as the loss of exclusivity of major assets.
Since 2018, he is responsible for Market Access for Vifor’s global nephrology portfolio. Before that, he held roles of increasing responsibility at Roche, AbbVie, Amgen, and Pfizer. Thilo holds a doctorate in health economics from the University of Mannheim and a dual degree in political sciences and economics.
Monika Szkultecka - Debek
Vice president of Qualitas Vitae Institute Foundation.
Monika Szkultecka – Debek, MD, PhD, Vice president of Qualitas Vitae Institute Foundation.
Monika Szkultecka – Debek, MD, PhD has medical education and is post graduate in Health Economics.
With over twenty years of experience in the pharmaceutical industry initially she focused her work on clinical research, and then on market access, specifically on activities related to HTA, health economics and outcomes research, Quality of Life and real world data. Contributed to a number of international conferences as speaker, organized and delivered international training on HTA, RWD and QoL. Cooperated with Warsaw University (reviews of master’s theses focused on HTA) and with Koźminski University in Warsaw (workshops at Health Economics and Big Data Master Studies).
Author and co-author of numerous scientific publications related to QoL, RWD and HTA, books, e.g. QoL English – Polish Dictionary, Polish ISPOR Chapter Pricing and Reimbursement Dictionary, Polish QoL Lexicon, chapters in students books related to: QoL and RWD, book chapter about use of RWD in pharmacoeconomics. She has a long history as a reviewer in several specialist journals. Member of the Editorial Advisory Board of the Journal of Health Policy and Outcomes Research (JHPOR) and from 2017 until present Deputy Editor in Chief of JHPOR.
Since April 2021 Vice president of Qualitas Vitae Institute Foundation.
Dr. Marco Rauland
VP, Global Market Access & Pricing - Strategic Planning, Merck KGaA
Marco Rauland has more than 25 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck, Marco was Vice President Europe of GfK’s Market Access practice. Before that Marco was the global head of the pricing, access and reimbursement practice of Genactis and Senior director of the pricing and reimbursement business unit at TNS Healthcare (now Kantar Group).
Marco is an expert in global pricing, listing and reimbursement strategy and has extensive experience in implementing pricing, access and reimbursement solutions at all stages of the product life cycle, from early product development to post-launch pricing strategies. He has developed the pricing, access and reimbursement strategy for product launches across numerous therapy areas and has in-depth knowledge of international country pricing & reimbursement systems. Marco studied Biochemistry and Pharmacology at the University of Cologne and holds a PhD in Natural Science.
Executive Director, International Regulatory Affairs, Alexion Pharma GmbH
Marta Parmar is the Head of International Regulatory Affairs at Alexion. Dr Parmar has over 18 years of combined R&D and regulatory strategy experience. She joined Alexion, AstraZeneca Rare Disease, in 2019 and has taken the role of Lead for the International Region shaping the regulatory environment for medicines under development for rare diseases in markets outside of the US and Japan. She received her PhD in Molecular Biology from the University of Zürich where she is currently based.
Alexander Natz, LL.M.,
Secretary-General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Alexander Natz is the Secretary-General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.
From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry. As a research assistant at Duke University (USA), he has dealt with international pharmaceutical law. His doctorate was supervised by the former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.
Global Market Access Director, Novartis
More than 15 years of experience in pharmaceutical industry in different geographies around the world, held several positions in commercial, marketing, sales and market access. Physician by training, post-graduate in Hospital Administration and Executive MBA from Universidad de Los Andes, EQUIS-Accredited. Lead several innovation projects for Novartis in Latin –America, Europe and Asia Pacific.
Maarten Van Baelen
Executive Director, Plasma Protein Therapeutics Association
Maarten is the Executive Director of the Plasma Protein Therapeutics Association (PPTA). The PPTA is a dynamic trade association that represents a unique sector of the biologics and biotechnology industry. PPTA represents more than 900 human plasma collection centers in North America and Europe, as well as, the manufacturers of lifesaving plasma protein therapies. PPTA’s mission is to drive broad and reliable access to plasma protein therapies, with a focus on the well-being of patients and plasma donors.
Prior to joining PPTA in 2019, Maarten worked as Market Access Director and Medical Affairs Manager at Medicines for Europe, the trade association representing the European generic, biosimilar and valued added pharmaceutical industries. In addition, during that time, Maarten was advisor to the Board of the European Medicines Verification Organization (EMVO).
After graduating as a pharmacist from KU Leuven, Maarten spent several years working in medical affairs roles in the pharmaceutical and medical devices industry. Maarten also obtained an MBA from the Solvay Brussels School Economics & Management and the École des Ponts Business School in Paris.
Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
Eugean Jiwanmall’s past professional experiences include basic science and clinical research. In his current role as a Senior Research Analyst for Medical Policy & Technology Evaluation at Independence Blue Cross’ Medical & Claim Payment Policy Department within Facilitated Health Networks and Medical Affairs, he has served as the subject-matter-expert, writer, reviewer, communicator, presenter, consultant, adviser/facilitator, and decision-maker for hundreds of medical policy topics and technology assessments within dozens of clinical disciplines and multiple business areas. Eugean has participated in numerous roles & capacities in a number of conferences, summits, and other national & international events etc. upon invitations. He has been invited by renowned organizations, evaluator bodies, & thinktanks etc. to be a key informant on a variety of complex and challenging topics, and recognized in communications & publications for these works.
Eugean has taken and completed graduate coursework in bioethics at the University of Pennsylvania School of Medicine. He holds a bachelor’s degree in biological sciences with honours from Drexel University (minor was in business administration), a master’s degree in public health in evaluative clinical sciences from Dartmouth Medical School, and an MBA in healthcare management and economics with honours from Drexel University.
Market Access & Government Affairs Lead, Miltenyi Biomedicine
Jörg Mahlich is Market Access & Government Affairs Lead at Miltenyi Biomedicine. Previous to that he held several Market Access and Health Economics positions in Germany and Japan at Janssen pharmaceuticals. He is a research affiliate at the Düsseldorf Institute for Competition Economics (DICE) of the University of Düsseldorf/Germany and teaches Health Economics at the Economics Department of the University of Vienna. He is interested in pharmaceutical economics and policy including HTA. He graduated in economics from the University of Kiel/Germany and holds a doctoral degree in economics from the University of Vienna/Austria.
Market Access Lead Europe/International, Regeneron
Olga Katzelnik leads Market Access for Regeneron outside of US. She has more than 12 years of experience in pharmaceutical industry across different geographies. Before joining pharmaceutical industry, Olga worked at Boston Consulting Group across various international Healthcare companies.
Olga is an expert in market access, reimbursement and pricing strategy as well as strategic planning and business development and has extensive global, regional and local experience in implementing access solutions at all stages of the product life cycle. She is also very engaged in mentoring digital health care start-ups in international accelerator programs. Olga holds Master of International Health Care Management, Economics and Policy from SDA Bocconi in Milan.
Head Real World Evidence Services, Novartis
Gilles Ducorroy is currently the Global Head of RWE Novartis services and has more than 25 years in the Pharma Industry, where he is working with statisticians, programmers, data scientists, health economists and bioinformaticians. Before taking his RWE role, Gilles was in charge of a Global HEOR team and also spent more than 7 years as a Market Access Head in Ireland. Gilles is also part of the Galway University Health Economics MSc programme board and involved with Trinity College in their Health Services Management MSc programme. Gilles is passionate about Access and healthcare systems.
Senior Representative 12
Global Head of Strategic Market Access Initiatives and Tech Partnerships, Boehringer Ingelheim
Oncology Market Access Strategy Leader, Bayer
Senior Statistical Science Director, AstraZeneca
Mario Ouwens is a PhD in biostatistics and is group director in medical and payer evidence statistics at AZ covering a group of 8 people working in observational research, IVS and health economics. Starting his career in banking industry, he proceeded to work as a statistician and health economic modeler for health economics and is referenced in NICE DSU technical support document 14, 16 and 21, among others. During the past years he presented several times on the ISPOR Europe podium (2017, 2018, 2019) in oral presentations and workshops and will present again in December 2021 in a workshop around the use of expert opinion in Bayesian analyses for survival extrapolation. During the past years he presented at PPMA and several other congresses as well. His work around treatment switching and survival extrapolation is published in Value in Health, Pharmacoeconomics and Medical Decision Making, among others.
Head of Market Access, Oxford AHSN
Dr Andy Stainthorpe’s career started in research with him gaining a PhD in Biochemistry (London), followed by a Fellowship in Genetics at the University of Warwick. He moved into national Policy development and lead for International activities with UK Research Councils working in a liaison capacity with UK Centres of Excellence and the European Commission.
He then returned to research as head for the Bristol NHS Research Development Unit. In this role he specialised in research trial design and assessment with a focus on outcome measures relevant to comparative assessment and health economics analysis. He contributed to many national and international projects in diverse fields including telemedicine, urology, emergency medicine and primary care service delivery.
His interest in research design standards led him to set up and be the first Director of the UK’s Research Integrity Office (UKRIO) in 2006 and also set up the European Network for Research Integrity (ENRIO).
He then joined NICE to set up the process and the unit which reviews liaises with pharmaceutical companies to develop and assess Managed Entry schemes (Patient Access Schemes). Managed entry proposals are key component of NICE Technology Appraisals, and mechanisms to gain access to NHS reimbursement.
More recently he has been working with the Oxford Academic Health Science Network (AHSN) to develop the scope Strategic Industry Partnership (SIP) to improve the evidence for innovation, working with companies and other partners to accelerate health and economic gains.
Sr. Director, Global Market Access & Pricing Governance, Shionogi
Head of Global Diabetes Solutions, Sanofi
Senior Representative 19
Senior Representative 20
Senior Representative 21
Senior Representative 22
Senior Representative 23
Senior Representative 24
Senior Representative 25
Senior Representative 26
Senior Representative 27
Senior Representative 28
Senior Representative 29
Senior Representative 30
Senior Representative 31
Senior Representative 32